AB0942 ANTI-IL17 TREATMENT AND INCIDENCE OF INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS

Background A warning about appearance or worsening of inflammatory bowel disease (IBD) during treatment with anti-IL17 agents has been launched by regulatory agencies in the last years. This caution is based on relationship between (IBD), joint (spondyloarthritis [SpA]) and skin (psoriasis [Ps]); regarding immune aspects. As well, drugs have proved ineffective IBD treatment. [1,2] Objectives To analyze incidence patients SpA Ps treated drugs. Methods systematic review clinical trials performed using 4 databases (Medline, Embase, Web Science, Cochrane Library). There were identified papers assessing trial’s participants, previously diagnosed SpA, global rate (IR), ratio (IRR) relative risks (RR) estimated this population, paralell crossover studies. Heterogeneity risk bias also evaluated. Results 53 finally selected for performing meta-analysis. IR diagnosis Ps/SpA under was 0.3/100 patients-year (95%CI 0.24-0.37). An IRR 0.56 0.34-0.9, p<0.01). RR 0.73 0.27-1.99, p=0.54) (Figure 1). Conclusion We cannot afirm that increase patients. Anti-IL17 may not be avoided practice concerning patients, due to prevention. References [1]McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R. The role IL-17A axial spondyloarthritis psoriatic arthritis: recent advances controversies. Ann Rheum Dis 2019 -09;78(9):1167-1178. [2]Moschen AR, Tilg H, Raine T. IL-12, IL-23 IL-17 IBD: immunobiology therapeutic targeting. Nat Rev Gastroenterol Hepatol -03;16(3):185-196. Figure 1. Relative parallel (a) (b) anti-IL17. Acknowledgements: NIL. Disclosure Interests None Declared.